Merck & Co Inc
MRK
NYSE
Pharmaceuticals
$148.99
USD
-3.21 (-2.11%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $329.55B
Volume 16.0M
Revenue
$66.57B
TTM
+4.6%
YoY
Gross Margin
73%
TTM
-4.7%
YoY
Net Income
$3.17B
TTM
-80.7%
YoY
Operating Cash Flow
$19.97B
TTM
+7.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 15,806.0 | 17,276.0 | 16,400.0 | 16,286.0 | 16,607.0 |
YoY Growth | -1.9% | +3.7% | +5.0% | +4.9% | +5.1% |
Cost of Revenue | 3,557.0 | 3,855.0 | 5,551.0 | 4,195.0 | 4,395.0 |
Gross Profit | 12,249.0 | 13,421.0 | 10,849.0 | 12,091.0 | 12,212.0 |
Selling, General & Administrative | 2,649.0 | 2,633.0 | 2,898.0 | 2,700.0 | 2,904.0 |
Other Operating Expenses | 560.0 | 47.0 | 213.0 | 195.0 | 151.0 |
Total Operating Expenses | 7,257.0 | 6,914.0 | 6,997.0 | 15,487.0 | 12,796.0 |
Operating Income | 4,992.0 | 6,507.0 | 3,852.0 | -3,396.0 | -584.0 |
EBITDA | 6,671.0 | 7,708.0 | 6,531.0 | -1,689.0 | 1,150.0 |
Other Income / Expense | 243.0 | 238.0 | -432.0 | -138.0 | 391.0 |
Total Other Income / Expense | 7.0 | 238.0 | -432.0 | -138.0 | -99.0 |
Income Before Income Taxes | 4,999.0 | 6,745.0 | 3,420.0 | -3,534.0 | -683.0 |
Income Taxes | 571.0 | 958.0 | 458.0 | 709.0 | 654.0 |
Net Income | 4,429.0 | 5,787.0 | 2,962.0 | -4,243.0 | -1,337.0 |
Consolidated Net Income / Loss | 4,428.0 | 5,787.0 | 2,962.0 | -4,243.0 | -1,337.0 |
Net Income Attributable to Common Shareholders | 4,427.0 | 5,785.0 | 2,963.0 | -4,240.0 | -1,335.0 |
Basic EPS | $1.76 | $2.32 | $1.19 | -$1.72 | -$0.54 |
Diluted EPS | $1.76 | $2.32 | $1.19 | -$1.72 | -$0.54 |
Basic Shares Outstanding | 2,510.0M | 2,495.0M | 2,480.0M | 2,472.0M | 2,470.0M |
Diluted Shares Outstanding | 2,513.0M | 2,498.0M | 2,486.0M | 2,472.0M | 2,470.0M |